MCRB
Seres Therapeutics, Inc.NASDAQHealthcare$9.27+4.63%ClosedMarket Cap: $88.9M
As of 2026-04-06
Valuation
P/E (TTM)
15.60
PEG
0.00
P/B
1.77
P/S
107.04
EV/EBITDA
17.42
DCF Value
$-3.20
FCF Yield
1.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-423.8%
Operating Margin
-11910.1%
Net Margin
721.9%
ROE
13.3%
ROA
4.1%
ROIC
-72.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $438.0K | 3251.8% | $-19.4M | $-15.3M | $-1.76 | — |
| FY 2025 | $789.0K | -423.8% | $-94.0M | $5.7M | $0.64 | — |
| Q3 2025 | $351.0K | -3704.0% | $-22.5M | $8.2M | $0.94 | — |
| Q2 2025 | $0.00 | -Infinity% | $-24.9M | $-19.9M | $-2.27 | — |
| Q1 2025 | $0.00 | -Infinity% | $-27.2M | $32.7M | $3.75 | — |
| Q4 2024 | $0.00 | NaN% | $-28.8M | $-15.6M | $-1.81 | — |
| FY 2024 | $0.00 | -Infinity% | $-121.3M | $136.0K | $-18.86 | — |
| Q3 2024 | $0.00 | -Infinity% | $-29.2M | $88.8M | $-7.59 | — |
| Q2 2024 | $0.00 | NaN% | $-28.9M | $-32.9M | $-4.34 | — |
| Q1 2024 | $0.00 | NaN% | $-34.4M | $-40.1M | $-5.49 | — |
| Q4 2023 | $64.0K | 100.0% | $-39.5M | $-41.2M | $-6.38 | — |
| FY 2023 | $0.00 | NaN% | $-195.1M | $-113.7M | $-17.77 | — |